Central Plains Eye MDs
Center for Glaucoma, Retina & Diabetic Eye Care
Call Today (316) 712-4970
Patient Portal

Completed Clinical Trials

Text Size A A A

Clinical trials provide many benefits. Great attention is directed to those enrolled in a trial, and participation typically incorporates a significant safety net for rescue therapy should a protocol not prove effective clinically. The number of people that may benefit from information learned through clinical trials is untold. Medicine would be hopelessly behind were it not for these physician and patient supported studies.

Thank you to those who participated in the following trials:

Age-Related Macular Degeneration

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

Sponsor: Alcon Research
ClinicalTrials.gov Identifier: NCT02307682 / 01.2015 – Current

Patient must be at least 50 years of age with active CVN lesions secondary to AMD that affects the central subfield with BCVA between 20/200 and 20/25.

Exclusions include: center subfield affected by fibrosis or GA, RPE rip/tear, current vitreous hemorrhage, intraocular or refractive surgery within 90 day of screening, stroke or myocardial infarction within 90 days of screening.

Enrollment status: CLOSED

Diabetic Macular Edema

A 6 month, Phase 2 Randomized, Controlled, Double-masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate (ALG-1001) as Compared to Avastin in the Treatment of Diabetic Macular Edema (DME)

Sponsor:Allegro Ophthalmics
ClinicalTrials.gov Identifier: NCT01482871 / 03.2015-Current

Patient must be at least 18 years of age with clinically significant Diabetic Macular Edema with central subfield thickness > 350µm on OCT and BCVA of 20/40 to 20/320.

Exclusions include: Active Proliferative Diabetic Retinopathy in the study eye, NVE, NVD, Vitreous hemorrhage or neovascular glaucoma, Uncontrolled hypertension, Screening HgA1c > 10.00 within last 3 months, High myopes > -8.00D, Focal laser or intravitreal/periocular steroids of any type in study eye, History of Rhegmatogenous retinal detachment, retinal tears, or traction retinal detachments, pars plana vitrectomy in study eye.

Enrollment status: CLOSED

Preserve

Pegaptanib (Macugen) in diabetic macular edema (DME)

Diabetic Macular Edema (DME) occurs when normal retinal blood vessels become damaged and leak both fluid and protein. This leakage distorts normal retinal architecture and leads to decreased visual acuity.Previous studies have shown that a peptide called VEGF165 is predominant in patients with DME. High levels of VEGF165 may cause the development and progression of diabetic macular edema and retinopathy. The purpose of this study was to evaluate the optimal dosing frequency of Macugen in eyes with Diabetic Macular Edema. This study involved men and women age 18 and older.

Participation in this study lasted approximately 24 weeks.
Enrollment status: CLOSED

Dr. Joe Beck is a caring soul. He and his staff listen to my concerns and patiently answer my many questions. I know I'm getting the most up-to-date and technologically advanced care. I trust Dr. Beck with my eyes. - William R., Judge